Bone Resorption Inhibitory Effects of Ethyl 4-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) and Related Compounds
; accepted December 1, 1998 In the course of our studies aimed at obtaining new drugs for treatment of bone and joint diseases, chemical modification of the potent bone resorption inhibitors justicidins, was performed and various naphthalene lactones, quinoline lactones and quinoline derivatives bearing an azole moiety at the side chain were prepared. Their inhibitory effects on bone resorption were evaluated by Raisz's method, and several compounds, including ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (6c, TAK-603), were found to have activities comparable with or superior to the justicidins. The 4-(3-isopropoxy-4-methoxy)-phenyl derivative (6d), in particular, displayed a marked increase in potency. TAK-603 and compound 6d were very effective in preventing osteoclast formation and bone resorption by mature osteoclasts. Further, TAK-603 was shown to be effective in preventing bone loss in ovariectomized mice.
was tried next in an attempt to improve the pharmacological properties, and it was found that activity was retained in the quinoline lactone derivatives (3a-c vs. 2a-c). This finding suggested that the quinoline ring was an effective core structure, encouraging us to introduce various heteroaryl moieties to the 2-methyl position, generated by ring opening of the lactone. The 2-(1-methylimidazol-2-ylthiomethyl)quinoline derivative (4a) was the first compound found with the desired biological activity in this series of compounds. Thus, further modification of 4a was performed.
Firstly, the effect of changing a heteroaryl moiety on the side chain at the 2-position of the quinoline skeleton was evaluated for compounds with a 1-methylimidazolyl (4a), a 4-methyltriazolyl (4b) or a thiazolyl (4c) moiety. These 2-azolylthio derivatives exhibited potent activity comparable with that of 4a. Compounds 4d-g represent variations of the 6,7-dimethoxy moiety on the quinoline ring possessing the 2-(1-methylimidazol-2-ylthio)methyl substituent. Among these derivatives, compounds bearing a 6,7-dialkoxy moiety (4a, 4d, 4e) had potent activity. This result is similar to that for the lactone derivatives. Concerning the substituents on the pendent phenyl ring at the 4-position, potent activity was observed for compounds with 4-methoxy (4h) and 4-methyl (4j) substituents, despite the reduction in activity with the unsubstituted compound (4l).
Although more data need to be accumulated for further discussion, we proceeded to explore the SAR around 4a. The activities of compounds 5 and 6a-c illustrate the influence of the linker between the quinoline and the heteroaryl rings. The sulfide moiety of 4a can be substituted with a methylene (5) or can be removed (6b, c). An abrupt increase in potency was achieved through replacement of the 3,4-dimethoxyphenyl group of 6c by a 3-isopropoxy-4-methoxyphenyl group (6d).
Compounds 2-6, which were derived from justicidins as lead compounds and found to possess antiresorptive activity, were evaluated for anti-inflammatory activity using an adjuvant arthritis model in the rat. Compounds 4, 5 and 6 had potent anti-inflammatory activity. 7) Among compounds possessing both antiresorptive and anti-inflammatory activities, 6c (TAK-603) was selected for clinical studies based on its pharmacological profile. 14) Compound 6d, which was synthesized during study of the metabolites of 6c, 1) exhibited reduced anti-inflammatory activity, 15) suggesting that some factors other than bone-resorbing function participate in adjuvant-induced inflammation.
Considering the biological results described above, two compounds, 6c (TAK-603) and 6d, were selected for detailed evaluation of antiresorptive activity. Ca release from bone induced by bone-resorbing factors, 16) human IL-1b, human parathyroid hormone (hPTH) and fetal bovine serum (FBS), was reduced by 6c and 6d (Table 5 ). Both compounds inhibited pit formation caused by pre-existing tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells (MNCs) on dentin slices. 17) Furthermore, new TRAP-positive MNC formation in culture dishes, without dentin slices, was also inhibited (Table 6 ). These results indicate that 6c and 6d inhibited both the activation of mature osteoclasts and the formation of new ones.
As shown in Table 7 , 6c was effective in an in vivo model, ovariectomized mice. In this model, 6c (TAK-603) had a preventive effect at an oral dose of 10 mg/kg/d. 18) Since the final stage of RA is bone destruction, the antiresorptive activity of 6c (TAK-603) may be useful in controlling cartilage destruction. Concerning 6d, in vivo studies using this model are presently under way.
In conclusion, we have found that quinoline derivatives bearing an azole moiety at the side chain of the 2-position have effects on bone metabolism as well as anti-inflammatory activity. Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603), which had the most promising profile 19) in this series of compounds, is expected to be useful as a new type of DMARD. Although several approaches to elucidate the detailed mechanism of TAK-603 are now in progress, we are convinced that the antiresorptive activity of this compound will be one of its most characteristic features as an antirheumatic drug. 
Experimental
Chemistry Melting points were determined on a Yanagimoto micromelting point apparatus and are uncorrected. Elemental analyses (C, H, N) were carried out by the Analytical Department of Takeda Chemical Industries, Ltd. 3,4-Methylenedioxycinnamyl 3,4-Methylenedioxyphenylpropiolate (9a) N,N-dimethylformamide (DMF) (1 drop) was added to a stirred mixture of 3,4-methylenedioxyphenylpropiolic acid (2.0 g, 11.0 mmol), (COCl) 2 (1.7 g, 13.2 mmol) in tetrahydrofuran (THF) (10 ml) at room temperature. The resultant mixture was stirred at room temperature for 1.5 h, and then concentrated in vacuo. A mixture of the residue obtained, pyridine (1.3 g, 16.0 mmol), 3,4-methylenedioxycinnnamyl alcohol (1.9 g, 11.0 mmol) and benzene (20 ml) was refluxed for 40 min. After cooling, the mixture was washed successively with 2 N aqueous HCl, H 2 O, saturated aqueous NaHCO 3 and brine, dried over MgSO 4 , and concentrated in vacuo. The residue was chromatographed on SiO 2 with AcOEt-hexane (2 : 3) to give 9a as pale yellow powder (1.4 g, 36%), mp 100-101°C. 1 
3,4-Methylenedioxycinnamyl 4-Methoxyphenylpropiolate (9c)
A solution of N,N Ј-dicyclohexylcarbodiimide (DCC) (2.6 g, 12.7 mmol) in pyridine (9 ml) was added dropwise to a stirred mixture of 3,4-methylenedioxycinnamyl alcohol (2.0 g, 11.5 mmol), 4-methoxyphenylpropiolic acid (2.0 g, 11.5 mmol), p-TsOH · H 2 O (120 mg, 0.63 mmol) and pyridine (29 ml) at room temperature. After stirring at room temperature for 5 h, AcOH (12 ml) was added, the mixture cooled to 0°C, and stirred for a further 2 h. The insoluble product was filtered off, the filtrate was diluted with H 2 O (100 ml), acidified with concentrated HCl, and then extracted with AcOEt. The combined extracts were washed successively with H 2 O, saturated aqueous NaHCO 3 and brine, dried over MgSO 4 and concentrated in vacuo to afford 9c as pale brown powder (72%), mp 100-102°C. 3. 37-3.42 (1H, m), 3.86 (3H, s), 3.99 (1H, t, Jϭ9 Hz) Ca (radioisotope of calcium in 45 CaCl 2 solution) (50 mCi) was subcutaneously injected into a Sprague-Dawley rat on the 18th day of pregnancy. On the next day, the abdomen was opened, and a fetus was aseptically removed. The left and right humeri (radii and ulnae) were removed under a dissecting microscope, and as much connective tissue and cartilage as possible were also removed. Bone culture samples were then prepared. The bone was incubated in 0.6 ml BCJ b medium (Fitton-Jackson modification; GIBCO Laboratories) containing 2 mg/ml bovine serum albumin at 37°C for 24 h in an atmosphere of 5% CO 2 air. The bones were transferred to further fresh medium containing the appropriate final dose of test compound, with or without stimulator, 3% FBS or hPTH (1-34, 100 ng/ml) or IL-1b (300 U/ml)). Bone was cultivated for 2 d in the resulting medium. The 45 Ca radioactivity in the medium and the 45 Ca radioactivity in the bone were determined. The ratio (%) of 45 Ca released from the bone into the medium was calculated from the following equation: ratio of 45 Ca released from bone into medium (%)ϭ Unfractionated Bone Cell Preparation Unfractionated bone cells were prepared according to the method of Takeda et al. 17) In brief, the femur and tibia of 11-to 13-day-old ICR mice (Japan Charles River, Tokyo, Japan) were aseptically isolated and minced with scalpel blades into 20 ml culture medium consisting of a-minimum essential medium (a-MEM) containing 5% FBS, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HE-PES) (pH 7.0), 100 mg/ml kanamycin, and 80 mg/ml gentamicin. The mixture of cell suspension and bone fragments was gently pipetted for 5 min and allowed to stand for 5 min. The resulting supernatant was used for the experiments. To determine the number of osteoclasts in the supernatant, an aliquot was smeared on a slide glass and stained for TRAP, a marker enzyme for osteoclasts, according to the method of Burstone. 20) TRAP-positive MNCs with three or more nuclei (roughly corresponding to 0.05% of the total cells) were counted as osteoclast-like cells.
Pit-Formation Assay Dentin slices of 0.1 mm-thickness and 6 mm-diameter were prepared by our previous method 21) and placed in a 96-well culture dish (Nunclon; Nunc, Roskilide, Denmark). The unfractionated bone cell suspension (4ϫ10 5 cells/dentin slice) with a TRAP-positive MNC density of 200 cells/dentin slice was seeded on to dentin slices and allowed to stand for 2 h at 37°C in a CO 2 incubator. After removal of nonadherent cells, the cells were further cultured for 4 d in medium containing several concentrations of test compound in the presence of 10 Ϫ8 M 1a,25-dihydroxyvitamine D 3 (1a,25(OH) 2 D 3 ). Experiments were completed by removing the culture medium and adding 0.1 M cacodylate buffer solution (pH 7.4) containing 2% paraformaldehyde. The total number of TRAP-positive MNC on each dentin slice was counted after TRAP staining of the cells. Cells were then removed from the dentin slices by ultrasonication for 30 s in distilled water, and air-dried. The slices were stained with hematoxylin and the number of densely stained pits was counted under light microscopy.
Osteoclast-Formation Assay 22) The unfractionated bone cell suspension (2ϫ10 5 cells/well) with a TRAP-positive MNC density of 100 cells/well was cultured in a 96-well plate without dentin slices in the absence of 1a,25(OH) 2 D 3 for 4 d. After depletion of TRAP-positive MNC was confirmed, the cells were further incubated for 6 d in culture medium containing test compound in the presence of 10 Ϫ8 M 1a,25(OH) 2 D 3 . The number of newly formed TRAP-positive MNC in the culture medium was then counted after TRAP staining of the cells. Our previous study demonstrated that preexisting TRAP-positive MNC were depleted by culturing in the absence of 1a,25(OH) 2 D 3 , but new TRAP-positive MNC formation is induced by the addition of 1a, 25(OH) 2 D 3 in culture dishes even after complete depletion of TRAP-positive MNCs.
Effect on Changes in Femoral Bone Weight in Ovariectomized Mice Thirteen-week-old female C3H mice were ovariectomized by a dorsal approach under ether anesthesia. Three weeks later, the right femur of each mouse was removed and cleaned of soft tissue. The dry weight of the femur, which was cut one-third from the distal end, was determined after heating at 110°C for 3 h in an oven. 6c was administered orally once a day for three weeks after the ovariectomy.
